Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc.

The publication follows the FDA's recent label expansion of EMPAVELI for patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative ...

Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ...

EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based ...

Weighted target price of ~$214 offers minimal upside relative to current levels; maintaining a Hold rating. The key challenge now is execution: Biogen must translate revenue growth into higher margins ...

Biogen Inc. (BIIB) is a global biotechnology company that develops and commercializes therapies for serious and complex diseases. Headquartered in Cambridge, Massachusetts, Biogen has built a strong ...

Biogen Inc. stock (ISIN US09062X1037) opened at USD 216.01 on Nasdaq on September 17, 2026, putting the biotechnology group ...

BOSTON--An injected version of Eisai and Biogen’s Alzheimer’s drug Leqembi works as well as the current intravenous ...

Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in ...

Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in ...

Biogen Inc. () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tool ...

US biotech Stoke Therapeutics (Nasdaq: STOK) and USA-based biotech major Biogen (Nasdaq: BIIB) have set out long-term results ...